Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BGIICC 2018 /
ESO-ESMO-ABC guidelines in metastatic breast cancer

18th - 19th Jan 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.01.18
Views: 4125

Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon

Dr Saghir speaks with ecancer at the 10th BGICC in Cairo about updates to international guidelines for diagnosis, staging and treatment of advanced breast cancer.

He discusses updates from the most recent ESO-ESMO meeting in Lisbon, including management of ER±, HER2± cancers.

Dr Saghir raises changing treatment options for patients, notably the range of approved CDK4/6 inhibitors and biosimilars.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation